Peroxisome proliferator-activated receptor-gamma is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Molecular Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 12391285
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy

  2002cited by this paper
• Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, modulates the E-cadherin/beta-catenin system in a human pancreatic cancer cell line, BxPC-3.

  2002cited by this paper
• The nonsteroidal anti-inflammatory drug sulindac causes down-regulation of signal transducer and activator of transcription 3 in human oral squamous cell carcinoma cells.

  2002cited by this paper
• Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice*

  2001cited by this paper
• Sulindac sulfide-induced apoptosis involves death receptor 5 and the caspase 8-dependent pathway in human colon and prostate cancer cells.

  2001cited by this paper
• Induction of Cytosolic Phospholipase A2 by Oncogenic Ras Is Mediated through the JNK and ERK Pathways in Rat Epithelial Cells*

  2001cited by this paper
• Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites.

  2001cited by this paper
• Cyclooxygenase‐independent actions of cyclooxygenase inhibitors

  2001cited by this paper
• Suppression of Intestinal Polyposis inApc Δ 716 Knockout Mice by an Additional Mutation in the Cytosolic Phospholipase A2Gene*

  2000cited by this paper
• A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis.

  2000cited by this paper
• Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer.

  2000cited by this paper
• Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis.

  2000cited by this paper
• Loss-of-function mutations in PPAR gamma associated with human colon cancer.

  1999cited by this paper
• Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signalling complex

  1999cited by this paper
• Metabolic targets of cancer chemoprevention: interruption of tumor development by inhibitors of arachidonic acid metabolism.

  1999cited by this paper
• Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2.

  1999cited by this paper
• PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs.

  1999cited by this paper
• Activators of the nuclear receptor PPARgamma enhance colon polyp formation.

  1998cited by this paper
• Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs.

  1998cited by this paper
• Activation of PPARgamma leads to inhibition of anchorage-independent growth of human colorectal cancer cells.

  1998cited by this paper
• Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice.

  1997cited by this paper
• Peroxisome proliferator-activated receptors and retinoic acid receptors differentially control the interactions of retinoid X receptor heterodimers with ligands, coactivators, and corepressors

  1997cited by this paper
• Peroxisome proliferator-activated receptor gamma: A key regulator of adipogenesis and systemic insulin sensitivity.

  1997cited by this paper
• Induction of Cytosolic Phospholipase A2 by Oncogenic Ras in Human Non-small Cell Lung Cancer*

  1997cited by this paper
• Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs.

  1997cited by this paper
• Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2).

  1996cited by this paper
• Discordant Signal Transduction and Growth Inhibition of Small Cell Lung Carcinomas Induced by Expression of GTPase-deficient G(*)

  1996cited by this paper
• Oncogenes and antioncogenes in lung tumorigenesis.

  1996cited by this paper
• The Peroxisome Proliferator‐activated Receptors: Ligands and Activators a

  1996cited by this paper
• Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent.

  1995cited by this paper
• 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma.

  1995cited by this paper
• Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer.

  1995cited by this paper
• An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).

  1995cited by this paper
• A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation.

  1995cited by this paper
• Interactions of PGH Synthase Isozymes‐1 and ‐2 with NSAIDs a

  1994cited by this paper
• Aspirin Use and Lung, Colon, and Breast Cancer Incidence in a Prospective Study

  1994cited by this paper
• Aspirin and the potential role of prostaglandins in colon cancer.

  1992cited by this paper
• Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines.

  1991cited by this paper
• Evidence for prostanoid biosynthesis as a biochemical feature of certain subclasses of non-small cell carcinomas of the lung as determined in established cell lines derived from human lung tumors.

  1989cited by this paper

• Treatment of non-small cell lung cancer using chem-bioinformatics-driven engineering of exosomal cargo-vehicle for telmisartan and pioglitazone targeted-delivery

  2025cites this paper
• Drug Repurposing in Non-Small Cell Lung Carcinoma: Old Solutions for New Problems

  2023cites this paper
• Targeting cancer-related inflammation with non-steroidal anti-inflammatory drugs: Perspectives in pharmacogenomics

  2022cites this paper
• Glial Cells in Alzheimer's Disease: From Neuropathological Changes to Therapeutic Implications.

  2022cites this paper
• Targeting Nuclear Receptors in Lung Cancer—Novel Therapeutic Prospects

  2022cites this paper
• Design, synthesis, and biological evaluation of novel sulindac derivatives as partial agonists of PPARγ with potential anti-diabetic efficacy.

  2021cites this paper
• Computational Drug Repurposing for Alzheimer’s Disease Using Risk Genes From GWAS and Single-Cell RNA Sequencing Studies

  2021cites this paper
• The effect of MEK1/2 inhibitors on cisplatin-induced acute kidney injury (AKI) and cancer growth in mice.

  2020cites this paper
• Celecoxib inhibits acute edema and inflammatory biomarkers through peroxisome proliferator-activated receptor-γ in rats

  2020cites this paper
• Celecoxib inhibits endometrial cancer cells through COX-2-dependent and non-dependent pathways

  2019cites this paper
• Astrocytes: Role and Functions in Brain Pathologies

  2019cites this paper
• Characterisation of the interleukin-4 signalling cascade involved in the induction of cyclooxygenase-2 and the polarisation of macrophages into an anti-inflammatory phenotype

  2018cites this paper
• IL-33 deficiency slows cancer growth but does not protect against cisplatin-induced AKI in mice with cancer.

  2018cites this paper
• PPARgamma-mediated ALDH1A3 suppression exerts anti-proliferative effects in lung cancer by inducing lipid peroxidation

  2018cites this paper
• Comparison of NSAIDs activity in COX-2 expressing and non-expressing 2D and 3D pancreatic cancer cell cultures

  2018cites this paper
• TARGETING THE PROSTACYCLIN/PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA AXIS IN LUNG CANCER CHEMOPREVENTION.

  2018cites this paper
• Methyl jasmonate enhances the radiation sensitivity of esophageal carcinoma cells by inhibiting the 11-ketoprostaglandin reductase activity of AKR1C3

  2018cites this paper
• Microglia and Astrocytes in Alzheimer's Disease: Implications for Therapy

  2017cites this paper
• PPAR Agonists for the Prevention and Treatment of Lung Cancer

  2017cites this paper
• ctPath: Demixing pathway crosstalk effect from transcriptomics data for differential pathway identification

  2017cites this paper
• Association between genetic polymorphisms of inflammatory response genes and the risk of ovarian cancer.

  2016cites this paper
• PPARγ as a Novel Therapeutic Target in Lung Cancer

  2016cites this paper
• Potentiation of indomethacin-induced anti-inflammatory response by pioglitazone in carrageenan-induced acute inflammation in rats: Role of PPARγ receptors.

  2016cites this paper
• Structural Characterization of Interactions between the Alzheimer’s Disease Amyloid-Beta Peptide and Small Molecules and Peptide Inhibitors

  2015cites this paper
• CD4 T cell knockout does not protect against kidney injury and worsens cancer

  2015cites this paper
• Mechanisms of peroxisome proliferator activated receptor γ regulation by non-steroidal anti-inflammatory drugs

  2015cites this paper
• A meta-analysis of the association of PPARγ rs1801282 polymorphism and NSAID usage with the risk of developing cancer.

  2014cites this paper
• Minireview: Challenges and opportunities in development of PPAR agonists.

  2014cites this paper
• Updates and Controversies in the Rapidly Evolving Field of Lung Cancer Screening, Early Detection, and Chemoprevention

  2014cites this paper
• Heterotrimeric G-Protein, Gα16, Is a Critical Downstream Effector of Non-Canonical Wnt Signaling and a Potent Inhibitor of Transformed Cell Growth in Non Small Cell Lung Cancer

  2013cites this paper
• NSAIDs Inhibit Tumorigenesis, but How?

  2013cites this paper
• β-carotene regulates expression of β-carotene 15,15'-monoxygenase in human alveolar epithelial cells.

  2013cites this paper
• Sulindac activates NF-κB signaling in colon cancer cells

  2013cites this paper
• Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib

  2013cites this paper
• COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs

  2013cites this paper
• Chemoprevention of Lung Cancer: Prospects and Disappointments in Human Clinical Trials

  2013cites this paper
• Lung cancer chemoprevention.

  2012cites this paper
• Protective effects of PPARγ agonist in acute nephrotic syndrome.

  2012cites this paper
• Expression of Peroxisome Proliferator Activated Receptor-Gamma (PPAR-γ) in Human Non-small Cell Lung Carcinoma: Correlation with Clinicopathological Parameters, Proliferation and Apoptosis Related Molecules and Patients’ Survival

  2012cites this paper
• Preclinical Predictors of Anticancer Drug Efficacy: Critical Assessment with Emphasis on Whether Nanomolar Potency Should Be Required of Candidate Agents

  2012cites this paper
• Indomethacin induces cellular morphological change and migration via epithelial-mesenchymal transition in A549 human lung cancer cells: a novel cyclooxygenase-inhibition-independent effect.

  2011cites this paper
• Criteria of evidence to move potential chemopreventive agents into late phase clinical trials.

  2011cites this paper
• Cross-kingdom actions of phytohormones: a functional scaffold exploration.

  2011cites this paper
• Activation of PPARγ in Myeloid Cells Promotes Lung Cancer Progression and Metastasis

  2011cites this paper
• Diclofenac: an update on its mechanism of action and safety profile

  2010cites this paper
• Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression.

  2010cites this paper
• A Novel Sulindac Derivative Lacking Cyclooxygenase-Inhibitory Activities Suppresses Carcinogenesis in the Transgenic Adenocarcinoma of Mouse Prostate Model

  2010cites this paper
• Peroxisome proliferator-activated receptor-gamma inhibits transformed growth of non-small cell lung cancer cells through selective suppression of Snail.

  2010cites this paper
• A Molecular Mechanism for Ibuprofen-Mediated RhoA Inhibition in Neurons

  2010cites this paper
• Anti-inflammatory and anti-oxidant neuroprotection in the prevention of Alzheimer's disease

  2010cites this paper
• Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1.

  2010cites this paper
• Transglutaminase-dependent antiproliferative and differentiative properties of nimesulide on B16-F10 mouse melanoma cells

  2009cites this paper
• Possible involvement of PPAR gamma in the regulation of basal channel opening of P2X7 receptor in cultured mouse astrocytes.

  2009cites this paper
• Chemoprevention of lung cancer.

  2009cites this paper
• Phase II Study of Celecoxib with Cisplatin Plus Etoposide in Extensive-Stage Small Cell Lung Cancer

  2009cites this paper
• Sulindac Enhances the Killing of Cancer Cells Exposed to Oxidative Stress

  2009cites this paper
• New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3.

  2009cites this paper
• Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells.

  2009cites this paper
• Rescue strategies against non‐steroidal anti‐inflammatory drug‐induced gastroduodenal damage

  2009cites this paper
• Primer: first do no harm—when is it appropriate to plan a cancer prevention clinical trial?

  2008cites this paper
• Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB.

  2008cites this paper
• Activation and Molecular Targets of Peroxisome Proliferator-Activated Receptor-γ Ligands in Lung Cancer

  2008cites this paper
• The Role of PPARγ in the Cyclooxygenase Pathway in Lung Cancer

  2008cites this paper
• Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer.

  2008cites this paper
• PPARγ: The Portrait of a Target Ally to Cancer Chemopreventive Agents

  2008cites this paper
• Role of NF-kappaB and PI 3-kinase/Akt in TNF-alpha-induced cytotoxicity in microvascular endothelial cells.

  2008cites this paper
• Prostacyclin Prevents Murine Lung Cancer Independent of the Membrane Receptor by Activation of Peroxisomal Proliferator–Activated Receptor γ

  2008cites this paper
• In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice

  2008cites this paper
• Prognostic and therapeutic implications of Apc mutations in colorectal cancer.

  2008cites this paper
• Sulindac Derivatives That Activate the Peroxisome Proliferator-activated Receptor γ but Lack Cyclooxygenase Inhibition

  2008cites this paper
• Akt-dependent heme oxygenase-1 induction by NS-398 in C6 glial cells: a potential role for CO in prevention of oxidative damage from hypoxia.

  2007cites this paper
• Celecoxib toxicity is cell cycle phase specific.

  2007cites this paper
• 15-Deoxy-Delta12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors.

  2007cites this paper
• Structure-based Inhibitor Design for an Enzyme That Binds Different Steroids

  2007cites this paper
• Antitumorigenic Effects of Peroxisome Proliferator-Activated Receptor-γ (PPAR γ ) in Non-small Cell Lung Cancer Cells (NSCLC) are Mediated by Suppression of COX-2 via Inhibition of NF-κ B *

  2007cites this paper
• Differential activity of sulindac metabolites against squamous cell carcinoma of the head and neck is mediated by p21waf1/cip1 induction and cell cycle inhibition

  2007cites this paper
• Peroxisome proliferator-activated receptor-gamma in lung cancer: defining specific versus "off-target" effectors.

  2007cites this paper
• The Activator Protein-1 Transcription Factor in Respiratory Epithelium Carcinogenesis

  2007cites this paper
• Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.

  2007cites this paper
• Antitumorigenic Effect of Wnt 7a and Fzd 9 in Non-small Cell Lung Cancer Cells Is Mediated through ERK-5-dependent Activation of Peroxisome Proliferator-activated Receptor γ*

  2006cites this paper
• The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR).

  2006cites this paper
• Effect of Simultaneous Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 in HER-2/Neu-Positive Breast Cancer

  2006cites this paper
• Cyclo-oxygenase 2 expression impairs serum-withdrawal-induced apoptosis in liver cells.

  2006cites this paper
• Protective effect of nonsteroidal anti-inflammatory drugs on colorectal adenomas is modified by a polymorphism in peroxisome proliferator-activated receptor δ

  2006cites this paper
• Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors

  2006cites this paper
• Peroxisome Proliferator‐Activated Receptors: Potential Therapeutic Targets in Lung Disease?

  2006cites this paper
• Differential regulation of anti-inflammatory proteins in human rheumatoid synoviocyte MH7A cell by celecoxib and ibuprofen.

  2006cites this paper
• Function of PPARgamma and its ligands in lung cancer.

  2006cites this paper
• Function of Pparγ and Its Ligands in Lung Cancer

  2006cites this paper
• Low Penetrance Alleles in Colorectal Cancer: the arachidonic acid pathway

  2006cites this paper
• Expression of peroxisome proliferator-activated receptor delta in human gastric cancer and its response to specific COX-2 inhibitor.

  2005cites this paper
• Alzheimer’s associated inflammation, potential drug targets and future therapies

  2005cites this paper
• Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics.

  2005cites this paper
• Wnt/β‐catenin‐pathway as a molecular target for future anti‐cancer therapeutics

  2005cites this paper
• The pathophysiological function of peroxisome proliferator-activated receptor-γ in lung-related diseases

  2005cites this paper
• Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model.

  2005cites this paper
• Role of nuclear receptors in lung tumourigenesis.

  2005cites this paper
• Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9

  2005cites this paper
• Nonsteroidal anti-inflammatory drugs and their analogues as inhibitors of aldo-keto reductase AKR1C3: new lead compounds for the development of anticancer agents.

  2005cites this paper
• New indications for established drugs: combined tumor-stroma-targeted cancer therapy with PPARgamma agonists, COX-2 inhibitors, mTOR antagonists and metronomic chemotherapy.

  2005cites this paper